Thermo Fisher Scientific Inc.
TMO
$609.82
+1.10%
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing analytical instruments, laboratory equipment, diagnostics consumables, and life science reagents to pharmaceutical, biotech, academic, and industrial customers. The company operates through four segments—analytical technologies, specialty diagnostic products, life science solutions, and lab products and services—making it a diversified and indispensable partner across the research and clinical value chain. As the largest player in the life science tools industry, Thermo Fisher is distinguished by its scale, broad portfolio, and strategic M&A capabilities. The current investor narrative centers on the company's ability to sustain mid-single-digit revenue growth and margin expansion in a post-pandemic environment, with recent quarterly results exceeding expectations and management raising long-term guidance, despite concerns about modest inflation and geopolitical tensions.…
TMO
Thermo Fisher Scientific Inc.
$609.82
Investment Opinion: Should I buy TMO Today?
Based on the analysis, I rate Thermo Fisher as a Buy. The company's strong operational performance, with 6.18% revenue growth and margin expansion, supports a positive outlook. The analyst consensus of 'Buy' with an average target of $632.58, implying 3.1% upside, aligns with this view, though the upside is modest.
Sign up to view all
TMO 12-Month Price Forecast
The AI assessment is bullish on Thermo Fisher over the next 12 months, driven by its consistent growth, margin expansion, and reasonable valuation relative to its history. The company's diversified portfolio and strong cash flow provide a solid foundation for continued success. However, the medium confidence reflects uncertainties around macro conditions and the stock's premium valuation. To upgrade to high confidence, we would need to see sustained revenue growth above 7% and margin expansion, while a downgrade would be triggered by a significant slowdown in growth or a major acquisition misstep.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $645.15 and implied upside of +5.8% versus the current price.
Average Target
$645.15
0 analysts
Implied Upside
+5.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
The target price range spans from $520.00 (low) to $750.00 (high), indicating a wide dispersion of expectations. The low target suggests a potential downside of -15.3%, possibly reflecting concerns about valuation or macroeconomic headwinds, while the high target implies a 22.2% upside, likely assuming continued margin expansion and robust demand for life science tools. Recent rating actions have been predominantly positive, with firms like Evercore ISI, Wells Fargo, and Barclays maintaining or reiterating Overweight/Buy ratings, while HSBC downgraded from Buy to Hold in June 2026. This mixed sentiment, combined with the wide target range, underscores the uncertainty around the stock's near-term valuation, though the overall consensus remains bullish.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. The bull case is anchored by consistent mid-single-digit revenue growth, margin expansion, and a diversified portfolio, while the bear case centers on valuation concerns and macro headwinds. Currently, the evidence slightly favors the bulls given the strong operational execution and analyst support, but the stock's premium valuation leaves little room for error. The most critical tension is whether the company can sustain its growth trajectory and margin improvements to justify its forward PE of 22.3x, or if inflationary pressures and geopolitical risks will dampen earnings growth, leading to multiple compression.
Bullish
- Strong Revenue Growth Momentum: Q1 2026 revenue grew 6.18% YoY to $11.005 billion, with sequential acceleration from Q4 2025's 7.2% growth. This demonstrates sustained demand across life science tools and diagnostics, underpinning the company's ability to execute in a normalized post-pandemic environment.
- Margin Expansion Driving EPS Growth: Gross margin improved to 40.67% in Q1 2026 from 37.29% in Q2 2025, while operating margin reached 16.93%. This operational leverage, combined with a 4.44 EPS (up 11.3% YoY), supports the forward PE of 22.3x, which is reasonable for a company with this growth profile.
- Analyst Consensus Remains Bullish: With 26 analysts, the consensus rating is 'Buy' (mean score 1.57), and the average target price of $632.58 implies ~3.1% upside from the current price of $613.78. Recent upgrades from Evercore ISI, Wells Fargo, and Barclays reinforce positive sentiment.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $6.748 billion, providing ample capacity for debt reduction, acquisitions, and shareholder returns. This financial flexibility supports the company's strategic M&A-driven growth model.
Bearish
- Elevated Valuation vs. Historical Norms: The trailing PE of 32.6x is above the 5-year average of ~28x, and the PEG ratio of 4.54 suggests the stock is expensive relative to its growth rate. This leaves limited margin for error if earnings disappoint.
- Modest Growth Compared to Peers: Revenue growth of 6.18% YoY is solid but below the double-digit growth seen in 2021 and lags some high-growth life science tools peers. This slower pace may not justify a premium multiple over the long term.
- Geopolitical and Inflationary Pressures: Management flagged 'modest inflation' risk and Middle East tensions as potential headwinds. Supply chain disruptions or input cost inflation could compress margins, which are already under pressure from rising operating expenses.
- High Debt Levels: Debt-to-equity stands at 0.74, and interest expense of $354 million in Q1 2026 represents a significant fixed cost. While manageable, rising interest rates could increase borrowing costs and reduce net income.
TMO Technical Analysis
Thermo Fisher's stock is in a strong uptrend, with a 1-year price change of +25.39% and a 3-month change of +29.82%. The current price of $613.78 sits at 94.9% of its 52-week range (low $435.27, high $647.00), indicating the stock is trading near its highs, reflecting robust momentum and investor confidence. This positioning suggests the market is rewarding the company's operational execution and growth prospects, though it also raises the risk of short-term overextension.
Beta
0.85
0.85x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$647
Price range past year
Annual Return
+24.1%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | -1.1% |
| 3m | +29.9% | +3.0% |
| 6m | +31.3% | +15.4% |
| 1y | +24.1% | +16.2% |
| ytd | +2.9% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Thermo Fisher's revenue trajectory remains solid, with the most recent quarter (Q1 2026) generating $11.005 billion, up 6.18% year-over-year. This growth rate is consistent with the prior year's quarterly performance, which saw revenue ranging from $10.36 billion to $12.22 billion, indicating a stable, mid-single-digit growth profile. The company's diversified segments, including life science solutions and lab products, are driving this growth, while the specialty diagnostics segment has normalized from pandemic-era highs. The growth is supported by strong demand for bioproduction and research tools, though the pace is moderate compared to the double-digit growth seen in 2021.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given Thermo Fisher's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 32.61x, while the forward PE is 22.30x, implying the market expects significant earnings growth in the next year. This gap suggests that investors are pricing in a recovery in earnings, likely driven by margin expansion and continued revenue growth. The forward PE is more reasonable relative to historical norms, indicating that the stock may not be as expensive as the trailing multiple suggests.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher carries a debt-to-equity ratio of 0.74, with interest expense of $354 million in Q1 2026, which could pressure net income if rates rise. The company's operating margin of 16.9% is below its historical peak, and gross margin has fluctuated between 37% and 41% over the past year, indicating potential input cost volatility. Revenue growth, while positive, is modest at 6.18% YoY, and the company's reliance on continued M&A for growth exposes it to integration risks. Free cash flow of $6.748 billion is strong, but a significant portion is used for debt servicing and acquisitions, limiting flexibility for other uses.
